Prognostic Impact of Discharge Transprosthetic Tricuspid Gradient After Transcatheter Tricuspid Valve Replacement
JACC: Cardiovascular Interventions · 2026-10
DOI: 10.1016/j.jcin.2026.10.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-10. Verfasst von Matteo Biroli und 51 weiteren Autor:innen. Beteiligte Einrichtung: Centro Cardiologico Monzino IRCCS, Milan, Italy. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although transprosthetic gradients are established prognostic markers after left-sided valve interventions, the prognostic significance of discharge tricuspid gradient (dTVG) after transcatheter tricuspid valve replacement (TTVR) remains unclear. OBJECTIVES: This study sought to evaluate the association between dTVG and clinical outcomes after TTVR and identify high dTVG determinants. METHODS: TRIPLACE (Global Multicenter Registry on Transcatheter Tricuspid Valve Replacement) is an international, multicenter TTVR registry. A discharge landmark analysis was performed, excluding patients with in-hospital mortality, lack of TTVR technical success, missing dTVG, or unavailable follow-up at any time point. Endpoints included all-cause mortality and the composite of all-cause mortality or heart failure hospitalization. The optimal dTVG cutoff was identified through quartile-based survival analysis and confirmed by log-rank maximization. Multivariable Cox models were developed using cross-validated candidate variable selection. RESULTS: Among 526 patients, 474 were included. Median follow-up was 208.5 days (Q1-Q3: 54-474 days). A data-driven dTVG cutoff of 3.5 mm Hg identified 122 of 474 patients (25.7%) with high dTVG. dTVG ≥3.5 mm Hg was associated with higher 1- and 3-year mortality (HR: 2.07; 95% CI: 1.14-3.75; P = 0.017 and HR: 2.07; 95% CI: 1.24-3.48; P = 0.006, respectively) and composite endpoint events (HR: 1.99; 95% CI: 1.31-3.03; P = 0.001 and HR: 1.96; 95% CI: 1.33-2.88; P < 0.001). After multivariable adjustment, dTVG ≥3.5 mm Hg remained associated with 3-year mortality (adjusted HR: 1.84; 95% CI: 1.09-3.10; P = 0.022) and the composite endpoint at 1 and 3 years (adjusted HR: 1.77; 95% CI: 1.16-2.70; P = 0.009 and adjusted HR: 1.77; 95% CI: 1.20-2.60; P = 0.004, respectively). Indexed inner transcatheter tricuspid valve diameter was the only potentially modifiable independent predictor of high dTVG (OR: 0.79 per 1 mm/m2 increase; 95% CI: 0.71-0.88). CONCLUSIONS: Elevated dTVG after TTVR independently identifies patients at increased risk of adverse outcomes. A 3.5 mm Hg threshold may support postprocedural risk stratification, whereas inner valve diameter represents a potentially modifiable determinant of elevated dTVG. (TRIPLACE [Global Multicenter Registry on Transcatheter Tricuspid Valve Replacement]; NCT06033274).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro Cardiologico Monzino IRCCS, Milan, Italy.
- Interventional Cardiology, Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA; Interventional Cardiology, White Plains Hospital,…
- Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Oregon Health and Science University, Portland, Oregon, USA.
- Centre for Heart Valve Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.
- Division of Cardiology, Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York, USA.
Zitieren
APA
Biroli, M., Scotti, A., Puri, R., Zahr, F., Boone, R., Kodali, S., Tchétché, D., De Backer, O., Coisne, A., Ludwig, S., Sturla, M., Stolz, L., Adam, M., Mangieri, A., Garcia, S. A., Ben Ali, W., Mahabadi, A. A., Ho, E. C., Cheung, A., …, & TRIPLACE Investigators (2026). Prognostic Impact of Discharge Transprosthetic Tricuspid Gradient After Transcatheter Tricuspid Valve Replacement. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2026.10.010
Vancouver
Biroli M, Scotti A, Puri R, Zahr F, Boone R, Kodali S, et al. Prognostic Impact of Discharge Transprosthetic Tricuspid Gradient After Transcatheter Tricuspid Valve Replacement. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2026.10.010
BibTeX
@article{Biroli2026,
author = {Biroli, Matteo and Scotti, Andrea and Puri, Rishi and Zahr, Firas and Boone, Robert and Kodali, Susheel and Tchétché, Didier and De Backer, Ole and Coisne, Augustin and Ludwig, Sebastian and Sturla, Matteo and Stolz, Lukas and Adam, Matti and Mangieri, Antonio and Garcia, Santiago A and Ben Ali, Walid and Mahabadi, Amir Abbas and Ho, Edwin C and Cheung, Anson and Echarte-Morales, Julio and von Stein, Philipp and Patrascu, Alexandru and Alnasser, Sami and Chadderdon, Scott and Cannata, Francesco and Kobari, Yusuke and Guddeti, Raviteja and Sievert, Horst and Byrne, Timothy and Maisano, Francesco and Frerker, Christian and Curio, Jonathan and Dumonteil, Nicolas and Oliva, Omar A and Rudolph, Tanja K and Kirchner, Johannes and Rudolph, Felix and Krishnaswamy, Amar and Kapadia, Samir R and Portillo, Juan Del and Rodés-Cabau, Josep and Schofer, Niklas and González, Ignacio Cruz and Estevez-Loureiro, Rodrigo and Granada, Juan F and Hausleiter, Jörg and Hahn, Rebecca T and Modine, Thomas and Fam, Neil and Latib, Azeem and De Marco, Federico and TRIPLACE Investigators, TRIPLACE Investigators},
title = {Prognostic Impact of Discharge Transprosthetic Tricuspid Gradient After Transcatheter Tricuspid Valve Replacement},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
doi = {10.1016/j.jcin.2026.10.010}
}
EUVIMED